Researchers at UC San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays.

First-in-Class Non-Invasive Ventilator Weaning Technology Fully Enrolled in Global Randomized Controlled Trial; Public Results Presentation Planned for late 2026 CRESTWOOD, KY, March 3, 2026 — Liberate Medical, a clinical-stage medical device company developing breakthrough neuromuscular electric

NPCD endorsed by the American Venous Forum and the American Venous and Lymphatic Society as an effective option for lymphedema management.

Koya CEO Andy Doraiswamy will highlight the company’s growth and commercial momentum for its portfolio—including Dayspring®.

Leading Podiatry Experts Issue Consensus to Drive Prevention Programs and Policies

Andy brings more than 25 years of experience in the medical device industry, with extensive expertise in commercial leadership and launching innovative therapies that solve unmet clinical needs and increase patient access in cardiovascular diseases.

Procyrion’s Aortix™ Percutaneous Mechanical Circulatory Support Device to be Showcased at TCT 2021 Annual Meeting

CEO Andy Doraiswamy and CFO Damian Rippole will highlight ongoing clinical research, provide updates on commercial momentum, its vascular pipeline

BERKELEY, Calif. — (November 20, 2025) — Channel Medsystems, Inc.,  a privately held company dedicated to advancing women’s health with innovative solutions, announced today the appointment of Robert Brown, MBA, CPA, as Chief Financial Officer. Mr. Brown is a seasoned financial executive with deep expertise in strategic finance, operations, and growth planning for healthcare and

Michael Levin-Epstein from Health Innovation Matters, chats with Tara Murphy, Vice President of Marketing at Channel Medsystems, Inc. Together, they discuss Tara’s background and how she came into her role at the company; the commercialization of the company’s flagship product, Cerene, an endometrial cryotherapy device; how market development, brand strategies, and patient engagement have fallen

San Francisco, Calif. — (November 6, 2025) — Channel Medsystems, a commercial-stage women’s health company, today announced that more than 5,000 women have now been treated with the Cerene® Cryotherapy Device, underscoring the growing clinical and commercial adoption of the company’s innovative solution for heavy menstrual bleeding (HMB) and dysmenorrhea. Cerene is an FDA-approved endometrial

CEO Andy Doraiswamy will discuss the company’s latest clinical research, strategic growth plans, commercialization progress of its products

/PRNewswire/ — SecondWave Systems, Inc., a clinical stage medical device company developing a novel ultrasound-based treatment for inflammatory disorders,…

Podimetrics, an innovative company specializing in complex diabetes care, has launched SmartMat+

Ascension Wisconsin is the first in the state to offer a groundbreaking, minimally invasive treatment aimed at providing women suffering from heavy periods with a safe and more convenient path to relief. The procedure uses advanced cryotherapy technology to ablate the uterine lining, significantly reducing heavy menstrual bleeding and cramping. Performed in a physician’s office